Britain and America have forged a important bilateral deal that will preserve zero levies on British drug shipments entering the American market.
Key Provisions of the Accord
As part of the deal, the UK has committed to boost expenditure on drugs through the public health system. This commitment secures that tariffs on these key exports will be held at nothing for a period of the next three years.
This deal is in response to recent statements to significantly raise tariffs on branded drug products, with potential rates mentioned as high as double the cost.
"This agreement with the Britain bolsters the worldwide climate for innovative medicines and establishes much-needed fairness to U.S.–U.K. medicine commerce," an announcement said.
Economic Importance
Medicines are one of the Britain's largest exports to the America, which is by far the primary destination for large British pharmaceutical firms.
Export figures indicate that in the one-year period prior to last September, the UK shipped drugs valued at £11.1bn to the US. This value accounted for a significant portion of all goods exports in that timeframe.
"This deal secures work, increases investment and sets the stage for the UK to become a global hub for biotech and pharma," a minister remarked.
Specific NHS Changes
The agreement includes several key commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the price threshold at which it judges new treatments to be too expensive by 25%.
- Higher Drug Budget: There is a goal to increase total public funding on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the coming ten years.
- Rebate Cap: The sum drug companies must refund to the NHS to stay within budget will be limited at 15%. In the past, rebates topped 20%.
Recent Tensions
The deal follows a long-running dispute between the pharmaceutical industry and the British authorities over drug pricing and approval rates.
These tensions were heightened by claims that US consumers were charged a premium for the equivalent treatments than consumers in the other developed nations.
Over the last 18 months, several large drug company projects in the UK have been delayed or cancelled, while multi-billion-dollar investments have been announced toward US facilities.
A senior figure publicly accepted that the NHS must spend more on treatments, noting that its spending on drugs had decreased as a share of its overall budget over the last ten years.
